Press Releases
Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders
Draig Therapeutics Presents New Phase 1 Data Demonstrating Safety, Tolerability, Pulsatile PK and Target Engagement by DT-101, a Novel AMPA Receptor Potentiator, at ASCP Annual Meeting
Draig Therapeutics to Present at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting
Draig Therapeutics to Participate in the Stifel 2026 Virtual CNS Forum
Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer
Draig Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of DT-101 for the Treatment of Major Depressive Disorder
Draig Therapeutics Appoints Experienced Biotech Leader Douglas E. Williams, Ph.D. as Chair of its Board of Directors
Draig Therapeutics Launches with $140 Million (£107 Million) Total Investment to Advance its Portfolio of Next-Generation Therapies for Major Neuropsychiatric Disorders
Publications
ASCP Presentation: DT-101 | a Novel AMPAR PAM Demonstrating Favorable Tolerability, PK and Target Engagement in Phase 1 Healthy Volunteer Trial
ASCP Poster Presentation: DT-101 – A Novel AMPAR PAM Demonstrates Favorable Tolerability and Functional Biomarkers in Phase 1 Healthy Volunteer Trial
ASCP Poster Presentation: Magnetoencephalography (MEG) in a First-in-Human Trial toDemonstrate the Functional Consequences of Target Engagement by DT-101,a Novel AMPA Receptor Positive Allosteric Modulator
Events
Key Literature
- DT-101
Enhancing plasticity to treat depression and other central nervous system diseases using event-driven pharmacology
- DT-101
AMPA receptor modulation in depression: from molecular mechanisms of plasticity to therapeutic translation
- DT-101
Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments
- DT-101
Synaptic priming: a framework for pharmacotherapy in depression
- DT-101
All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants
- DT-201
Negative allosteric modulation of GABAARs at α5 subunit-containing benzodiazepine sites reverses stress-induced anhedonia and weakened synaptic function in mice
- DT-101
Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile
- DT-201
A Negative Allosteric Modulator for ⍺5 Subunit-Containing GABA Receptors Exerts a Rapid and Persistent Antidepressant-Like Action without the Side Effects of the NMDA Receptor Antagonist Ketamine in Mice
- DT-101
Integration of lead optimization with crystallography for a membrane-bound ion channel target: discovery of a new class of AMPA receptor positive allosteric modulators
- DT-301
Preclinical and clinical pharmacology of TPA023B, a GABAA receptor α2/α3 subtype-selective partial agonist
- DT-101
Challenges for and current status of research into positive modulators of AMPA receptors
- DT-301
Subtype-selective GABA(A) receptor modulation yields a novel pharmacological profile: the design and development of TPA023
- DT-201
Preclinical and clinical pharmacology of the GABAA receptor alpha5 subtype-selective inverse agonist alpha5IA
- DT-201
In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist
The Future of Brain Health Starts Here
Whether you're a patient, caregiver, researcher, investor, or member of the press, we'd love to hear from you.